Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W T Beck

Showing results (11-20 of 103) with videos related to

Pageof 11
Sort By:
Cytotechnology|January 1, 1996
Unanswered questions about multidrug resistanceW T Beck
Journal of the National Cancer Institute|November 15, 1989
Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistanceW T Beck
Oncology Research|January 1, 1995
DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublinesM Chen, W T Beck
Molecular Pharmacology|March 3, 1999
Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like proteaseT Khélifa, W T Beck
Cancer Research|April 1, 1995
Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26M Chen, W T Beck
Biochemical Pharmacology|February 15, 1983
Impairment by ruthenium red of anticancer drug cytotoxicity in CCRF-CEM cellsV Conter, W T Beck
Biochemical Pharmacology|September 16, 1999
Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cellsT Khélifa, W T Beck
Cancer Research|December 29, 1998
Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53Q Wang, W T Beck
Cancer Research|December 15, 1993
Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzymeM Chen, W T Beck
Cancer Research|September 15, 1994
Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26R Kim, W T Beck
Pageof 11

Showing results (11-20 of 103) with videos related to

Sort By:
Pageof 11
Cytotechnology|January 1, 1996
Unanswered questions about multidrug resistanceW T Beck
Journal of the National Cancer Institute|November 15, 1989
Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistanceW T Beck
Oncology Research|January 1, 1995
DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublinesM Chen, W T Beck
Molecular Pharmacology|March 3, 1999
Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like proteaseT Khélifa, W T Beck
Cancer Research|April 1, 1995
Differences in inhibition of chromosome separation and G2 arrest by DNA topoisomerase II inhibitors merbarone and VM-26M Chen, W T Beck
Biochemical Pharmacology|February 15, 1983
Impairment by ruthenium red of anticancer drug cytotoxicity in CCRF-CEM cellsV Conter, W T Beck
Biochemical Pharmacology|September 16, 1999
Induction of apoptosis by dexrazoxane (ICRF-187) through caspases in the absence of c-jun expression and c-Jun NH2-terminal kinase 1 (JNK1) activation in VM-26-resistant CEM cellsT Khélifa, W T Beck
Cancer Research|December 29, 1998
Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53Q Wang, W T Beck
Cancer Research|December 15, 1993
Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzymeM Chen, W T Beck
Cancer Research|September 15, 1994
Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26R Kim, W T Beck
Pageof 11